Fetal Secretory IgA Delivery via Transamniotic Fetal Immunotherapy (TRAFIT) in a Rodent Model.

Autor: Whitlock AE; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Moskowitzova K; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Labuz DF; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Sewall N; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Mullin K; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Kycia I; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Zurakowski D; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA., Fauza DO; Department of Surgery, Boston Children's Hospital/Harvard Medical School, Boston, MA, USA. Electronic address: dario.fauza@childrens.harvard.edu.
Jazyk: angličtina
Zdroj: Journal of pediatric surgery [J Pediatr Surg] 2023 Oct; Vol. 58 (10), pp. 2050-2053. Date of Electronic Publication: 2023 Mar 15.
DOI: 10.1016/j.jpedsurg.2023.03.004
Abstrakt: Purpose: We sought to determine the feasibility and routing kinetics of transamniotic fetal delivery of secretory immunoglobulin-A (SIgA), in a rodent model.
Methods: Fetuses (n = 94) from seven time-dated pregnant dams received intra-amniotic injections on gestational day 17 (E17, term = E21-22) of either saline (n = 15) or a solution of 1 mg/mL of ≥95% homogeneous human SIgA (n = 79). Animals were euthanized daily at E18-E21 for quantification of the IgA component by ELISA at gestational membranes, placenta, and select fetal anatomical sites against saline controls procured at term. Statistical analysis was by Mann-Whitney U-test.
Results: None of the saline-injected animals had detectable human IgA. SIgA-injected fetuses showed human IgA in the stomach aspirate, intestinal wall, lungs, liver, and serum at all time points. IgA levels were significantly higher in the gastric aspirate and in the intestine than in all other sites (p < 0.001 for both), with intestinal levels remaining stable through E18-E21 (p = 0.09-0.62 pairwise). Serum and placental levels were consistently low throughout, reaching near zero levels by E21.
Conclusions: The chronology of exogenous secretory-IgA kinetics after intra-amniotic injection is suggestive of fetal uptake by ingestion, leading to consistent levels in the gastrointestinal tract. Transamniotic fetal immunotherapy (TRAFIT) with secretory-IgA may become a novel strategy for enhancing early mucosal immunity.
Level of Evidence: N/A (animal and laboratory study).
Type of Study: Animal and laboratory study.
(Copyright © 2023 Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: